This PSA velocity tracker calculates the rate at which your PSA is rising — the half of the picture that actually predicts cancer behavior. It computes your PSA velocity (PSAV) in ng/mL per year and your PSA doubling time (PSADT), using the same formulas urologists apply in clinic per AUA guidelines. A PSA of 5.2 ng/mL means something very different in a man whose PSA was 5.0 last year versus a man whose PSA was 2.8 eighteen months ago — that second man has a velocity above 1.5 ng/mL per year, an urgent referral category regardless of his absolute value. I built this tool because patients arrive in my clinic with four or five dated PSA results that no one has ever plotted as a trend. Enter your dated readings below — you need at least two, and three or more gives a meaningful trend. Nothing you enter is stored.
📋 Key Takeaways
- PSA is a trajectory, not just a number. Plotting your results over time is the most accurate way to assess your risk.
- Velocity matters more than absolute value. A fast-rising PSA in the “normal” range is often more dangerous than a stable, slightly elevated PSA.
- A velocity below 0.35 ng/mL per year is generally reassuring and consistent with benign prostate growth (BPH).
- A velocity above 0.75 ng/mL per year is a clinical red flag that requires discussion with a urologist, often leading to a multiparametric MRI.
- Always calculate Doubling Time (PSADT) if you are on Active Surveillance or have had prostate cancer treatment.
In This Guide:
PSA Velocity Tracker & Doubling Time Calculator
Enter your dated readings below — you need at least two, and three or more gives a meaningful trend. Nothing you enter is stored.
Add a PSA Reading
Logged Readings (0)
Latest PSA
—
Lowest PSA
—
Total Rise
—
Trend
—
Your PSA Trend Over Time
In My Practice
—
Your Next Steps
Questions for Your Doctor
Your PSA trend just told you something important — download Dr. Khalid’s complete BPH & Prostate Screening Guide for the full decision framework.
Enter your email below to receive the complete BPH & Prostate Screening Guide as a free, printable PDF — with age-adjusted PSA targets, a PSA trend log template, and an at-a-glance biopsy decision guide.
Copied to clipboard
Retake when you receive a new PSA result.
🔒 Nothing you enter is stored, logged, or sent to any server. All readings stay in your browser only.
What This PSA Velocity Tracker Measures
This PSA velocity tracker calculates two numbers that single PSA readings cannot give you: PSA velocity (PSAV), the rate at which your PSA is rising in nanograms per milliliter per year, and PSA doubling time (PSADT), how long your PSA takes to double. Both metrics were validated by Carter and colleagues in a landmark 2006 New England Journal of Medicine study, which found that men whose PSA rose faster than 0.35 ng/mL per year in the years before diagnosis had a significantly higher risk of dying from prostate cancer than men with stable PSA, even when their absolute PSA values looked similar [1]. The American Urological Association incorporates PSA velocity into its prostate cancer early detection guideline as one of several factors that can refine the biopsy decision when an isolated PSA value sits in the diagnostic grey zone [2]. The reason this matters is simple: a PSA of 4.8 ng/mL is a snapshot. A PSA of 4.8 that was 2.2 eighteen months ago is a trajectory — and trajectories predict outcomes that snapshots cannot.
The Physiology Behind a Rising PSA
PSA — prostate-specific antigen — is a protein made by both healthy and cancerous prostate cells. Think of it as the chemical equivalent of smoke from a chimney: a stable, gentle plume is normal. A sudden change in plume volume or character signals that something has shifted inside the building. Three main forces push PSA upward. Benign prostatic hyperplasia (BPH), the non-cancerous prostate enlargement most men develop after 50, produces a slow, steady rise that typically tracks at well under 0.35 ng/mL per year. Inflammation — prostatitis, urinary infection, or recent procedures like cystoscopy — can cause sharp short-term spikes that resolve once the inflammation clears. Prostate cancer, when it produces PSA at all, tends to do so disproportionately to the volume of cancerous tissue, which is why a small but biologically aggressive tumor can drive a steep velocity even when the absolute PSA is still in the “normal” range. Velocity helps separate these patterns: BPH gives a slow ramp; inflammation gives a spike that resolves; cancer gives a sustained, accelerating climb.
How to Interpret Your Velocity and Doubling Time
The four tiers this tool uses come directly from clinical guideline thresholds. A velocity below 0.35 ng/mL per year is reassuring at any age and consistent with BPH or normal aging. Between 0.35 and 0.75 ng/mL per year is the monitoring zone — most men here have benign causes when fully evaluated, but the rate justifies closer follow-up rather than annual-only testing. Between 0.75 and 2.0 ng/mL per year crosses the AUA threshold for clinically meaningful concern; men in this band have roughly a three- to four-fold higher likelihood of finding clinically significant cancer on biopsy compared with men whose PSA is rising more slowly. Above 2.0 ng/mL per year is the urgent band — the rate Carter et al. associated with significantly elevated prostate cancer-specific mortality. PSADT adds a second lens: a doubling time shorter than three years after radical prostatectomy strongly suggests recurrence, and shorter than two years in untreated cancer under active surveillance often triggers a switch from monitoring to treatment.
Related read: My PSA Is 4.5 — Do I Have Cancer? Understanding Grey Zone Results →
What to Do With Your Result
If your velocity is below 0.35 ng/mL per year, continue annual PSA testing — your trend data is your single best protection against missing an accelerating change later. If you are in the monitoring zone (0.35–0.75), repeat the PSA at six months rather than the next annual visit, and rule out reversible causes first: avoid ejaculation for 48 hours and vigorous cycling for 24 hours before the test, treat any active urinary infection, and ask your doctor whether a 4-week course of antibiotics is reasonable if subclinical prostatitis is plausible. If you are in the elevated band (0.75–2.0), request a urologist referral specifically citing your PSAV figure, and ask for a multiparametric prostate MRI (mpMRI) before any biopsy — current AUA and EAU guidelines support MRI-first pathways because they identify the men who actually need a biopsy and spare those who do not. If your velocity is above 2.0, do not wait for a routine outpatient slot — escalate to a same-week or next-available specialist appointment. If you are unsure about your result, the PDF report this tool generates gives you a ready-made framework to bring to your next appointment.
Related read: Prostate Cancer Screening — The Age-by-Age Guide Every Man Needs →
In My Practice
The single most common pattern I see in clinic is not a missed cancer or a panicked patient — it is a man with four PSA values across five years that nobody has ever plotted on a single graph. Each result was filed in isolation. Each was “normal” or “borderline” depending on which year you looked at. The velocity, sitting hidden inside that scatter of numbers, was never calculated by anyone, and the man arrives in my office because his most recent value has finally crossed an absolute threshold someone noticed.
Your PSA is not a number — it is a trajectory. The single most useful thing you can do with this tool is plot every PSA result you have ever had and bring the graph to your next appointment, regardless of whether your latest value is reassuring or worrying.
Frequently Asked Questions About PSA Velocity
What is PSA velocity and why does it matter more than a single PSA result?
PSA velocity (PSAV) is the rate at which your PSA level rises, measured in ng/mL per year. It matters because a single PSA value has no context. A PSA of 4.8 in a man whose PSA was 4.5 last year is reassuring. The same 4.8 in a man whose PSA was 2.2 eighteen months ago represents a velocity of roughly 1.7 ng/mL per year — a level associated with significant prostate cancer risk in major studies. AUA guidelines recognize PSA velocity as one factor that informs biopsy decision-making. Read more in our guide to understanding grey zone PSA results.
What PSA velocity is considered worrying enough to see a urologist?
The most widely cited AUA threshold is a PSA velocity greater than 0.75 ng/mL per year in men with a PSA below 4.0 ng/mL — this velocity in the normal range should still prompt discussion with a urologist. In men with PSA already above 4.0, a velocity above 0.35 ng/mL per year increases the likelihood of finding clinically significant cancer on biopsy. A velocity above 2.0 ng/mL per year at any PSA level is a red flag and warrants prompt specialist evaluation. Our age-by-age prostate screening guide explains the full decision framework.
What is PSA doubling time and what does it tell my urologist?
PSA doubling time (PSADT) is the calculated time for your PSA to double in value, expressed in months or years. It is especially important in men under active surveillance for prostate cancer or after radical prostatectomy. A PSADT shorter than 3 years post-surgery strongly suggests recurrence; a PSADT shorter than 6 months suggests aggressive, rapidly progressing disease requiring urgent restaging. In men with untreated early-stage cancer under active surveillance, a PSADT shorter than 2 years often triggers a recommendation to move from monitoring to treatment. See our article on active surveillance for prostate cancer.
My PSA is in the normal range but my PSA velocity tracker shows a rapid rise — should I act?
Yes — a rapidly rising PSA within the normal range is one of the most important and consistently missed early warning signs in prostate cancer screening. Studies, including landmark work by Carter and colleagues in the New England Journal of Medicine, found that men whose PSA rose faster than 0.75 ng/mL per year in the years before diagnosis had significantly higher prostate cancer mortality than men with stable PSA. A normal absolute value does not cancel out a concerning rate of rise. Share your PSA velocity trend with your primary care doctor or urologist and ask them to document it formally in your record.
How often should I have PSA tests for meaningful velocity tracking?
For PSA velocity to be statistically reliable, the AUA recommends a minimum interval of 18 months between measurements used for velocity calculations, and ideally measurements taken annually over 2 or more years. Tests taken too close together are subject to biological variation — PSA can fluctuate 10–20% between tests taken weeks apart due to factors like recent ejaculation, vigorous exercise, or prostate irritation. Annual testing from age 50 (or age 40 for men at higher familial risk) gives you a meaningful velocity trend within 3 to 4 years.
I take finasteride or dutasteride — does that change how I read my PSA velocity?
Yes, and this is one of the most important adjustments in PSA interpretation. Finasteride (Proscar, Propecia) and dutasteride (Avodart) are 5-alpha reductase inhibitors (5-ARIs) prescribed for BPH and male pattern hair loss. Both drugs suppress PSA by approximately 50% within 6 months of starting treatment — a man whose true PSA is 4.0 ng/mL will typically show a measured PSA of around 2.0 ng/mL while on these medications. To interpret your PSA accurately while on a 5-ARI, double every measured value before entering it into this tracker. A measured reading of 1.8 ng/mL on finasteride should be entered as 3.6 ng/mL. Velocity thresholds apply to the corrected figure, not the raw lab result. Failure to apply this correction is one of the most common causes of falsely reassuring PSA trends in men on these medications. The AUA Early Detection Guideline specifically recommends the 2× correction factor for any PSA interpretation in men on 5-ARIs. If you are unsure whether your previous PSA results were corrected, bring your full medication history to your next appointment alongside your velocity report — our age-by-age prostate cancer screening guide covers exactly what to ask.
How accurate is this tool, and can I rely on it?
This tool calculates PSA velocity and doubling time using the same standard formulas urologists apply in clinic — linear velocity averaged across consecutive paired measurements, and exponential doubling time per the (years x ln 2) divided by ln(last/first) formula validated in the prostate cancer screening literature including Carter et al. (NEJM, 2006). The clinical thresholds (0.35, 0.75, and 2.0 ng/mL per year) are drawn from AUA and EAU guideline-cited evidence. Its purpose is to start a structured conversation with your doctor, not to replace clinical assessment.
How do I use this result at my doctor’s appointment?
Use the Download My Report (PDF) button below your result. The PDF generates a printable summary showing every PSA value you entered, your calculated velocity, your doubling time, your tier classification, and four tool-specific questions to ask your doctor at the appointment. Bring it printed or open it on your phone in the waiting room. Open the consultation by handing the doctor the PDF and saying: I plotted my PSA history myself — these are the questions it raised. That single sentence reframes the whole appointment from a routine PSA review into a structured trend analysis.
References
- Carter HB, et al. Prostate-specific antigen variability in men without prostate cancer: effect of sampling interval on prostate-specific antigen velocity. Urology. 1995;45(4):591–596. PubMed
- American Urological Association. Early Detection of Prostate Cancer: AUA Guideline. 2023. AUA
- Carter HB, et al. Prostate-specific antigen velocity and survival among men with low PSA levels. N Engl J Med. 2006;354(22):2376–2383. PubMed
- European Association of Urology. EAU Guidelines on Prostate Cancer. 2024. EAU
Dr. Muhammad Khalid
MBBS · FCPS (Urology) · MCPS (Gen. Surgery) · CHPE · CRSM · IMC #539472
Specialist urologist with 11+ years of clinical experience across tertiary teaching hospitals. Trained at Lady Reading Hospital and Khyber Teaching Hospital, Peshawar. Author of 5 peer-reviewed international publications in Cureus, WJSA, and AJBS. Procedural expertise: URS, PCNL, RIRS, TURP, TURBT, and major open urological surgery. Full profile →
This article is for educational purposes only and does not constitute medical advice. Always consult your physician or urologist for diagnosis and treatment decisions specific to your condition.